# A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)

> **NCT07193550** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 70 (estimated)

## Conditions studied

- Bone Sarcomas

## Interventions

- **DRUG:** Zanzalintinib

## Key facts

- **NCT ID:** NCT07193550
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-05
- **Primary completion:** 2029-10-31
- **Final completion:** 2031-10-31
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07193550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07193550, "A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07193550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*